Comparing medication persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists in real-world setting
Weight changes Weight gain or weight loss, especially quickly or suddenly, often disrupts menstrual cycles
Frequently Asked Questions Will my insurance cover semaglutide or tirzepatide for weight loss
Bnh hin khng c cch cha
Abbreviations SGLT-2i: Sodium-dependent glucose transporters 2 inhibitors GLP-1 Ras: Glucagon-like peptide 1 COVTs: Cardiovascular outcomes trials MACE: Major adverse cardiovascular events HHF: Hospitalization for heart failure CV death: Cardiovascular death HHF or CV death: Hospitalization for heart failure or cardiovascular death MI: Myocardial infarction T2DM: Type 2 diabetes mellitus RoB 2: Risk-of-bias tool CIs: Confidence intervals HRs: Hazard ratios References Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, Stein C, Basit A, Chan JCN, Mbanya JC, et al